Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: Microbiology Devices Panel

This article was originally published in The Gray Sheet

Executive Summary

Microbiology Devices Panel: FDA advisory panel unanimously votes (5-0) in favor of downclassification of automated short-term incubation cycle antimicrobial susceptibility devices from Class III to Class II at a Feb. 13 meeting in Rockville, Maryland. BioMerieux Vitek requested the downclassification in a petition submitted to the agency on July 24, 1997 ("The Gray Sheet" Aug. 18, I&W-6). Special controls recommended by the panel include an updated version of FDA's "Review Criteria for the Assessment of Antimicrobial Susceptibility Devices"...

You may also be interested in...



ATAI Raises $125m Series C To Expand The Boundaries In Mental Health

The funding will be used to support clinical and preclinical development at its portfolio companies, with 8-10 programs in the clinic in 2021.

10 Predictions On How Health Policy Could Change Under A Biden Presidency

Health policy changes that President-elect Joe Biden will likely make during his four-year term include Medicaid expansion and a greater reliance on medical science, among others, experts say.

Hologic Aptima Assay Cleared For HIV Detection

Already cleared to monitor the viral load in HIV-positive individuals, the test has now been approved for initial diagnosis as well.

UsernamePublicRestriction

Register

SC143367

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel